Strides Pharma Science receives USFDA tentative approval for Triamcinolone Acetonide Ointment

Strides Pharma Science announced that its step]down wholly owned subsidiary, Strides Pharma Global, Singapore, has received tentative approval for Triamcinolone Acetonide Ointment USP, 0.05% from the United States Food & Drug Administration (USFDA).

While it was amongst the few Competitive Generic Therapy (CGT) designated products for Strides, another generic company received approval prior to the company's approval. Consequently, the final approval for Strides will be effective 30 May 2020 when the company will launch the product.

According to IQVIA MAT data, the US market for Triamcinolone Acetonide Ointment USP, 0.05% is approximately US$ 20 Mn. The product will be manufactured at the companyfs Oral dosage facility at Bangalore and will be marketed by Strides Pharma Inc. in the US market.

Powered by Capital Market - Live News